Zacks Research Has Bearish Forecast for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research cut their FY2025 EPS estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Thursday, November 28th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.09. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other equities research analysts have also recently issued reports on ESPR. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $3.25 on Monday. The company has a market cap of $640.38 million, a PE ratio of -5.08 and a beta of 1.01. The company has a 50-day simple moving average of $2.18 and a 200-day simple moving average of $2.17. Esperion Therapeutics has a 12 month low of $1.35 and a 12 month high of $3.44.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently made changes to their positions in the stock. BOKF NA bought a new position in Esperion Therapeutics in the 2nd quarter worth approximately $26,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics during the second quarter valued at approximately $28,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at $27,000. National Bank of Canada FI boosted its position in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics in the 2nd quarter valued at approximately $44,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.